Regulus Therapeutics traded at $2.69 this Tuesday April 9th, increasing $0.02 or 0.56 percent since the previous trading session. Looking back, over the last four weeks, Regulus Therapeutics gained 94.57 percent. Over the last 12 months, its price rose by 184.46 percent. Looking ahead, we forecast Regulus Therapeutics to be priced at 2.60 by the end of this quarter and at 2.38 in one year, according to Trading Economics global macro models projections and analysts expectations.
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases. Its product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a kidney disease. The Company completed Phase I multiple-ascending dose (MAD) clinical trial. RGLS4326, an anti-miR targeting miR-17, is for the treatment of autosomal dominant polycystic kidney disease (ADPKD). It is in Phase I clinical trial. The Company’s pre-clinical pipeline candidates include RGLS5579 and anti-miR-132. RGLS5579 is developing for the treatment of Glioblastoma and anti-miR-132 is developing for the treatment of non-alcoholic steatohepatitis. Its developing two undisclosed products under Cell Therapies program and Hepatitis B virus program.